Ondansetron Sandoz Ltd (Ondansetron)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the chemoreceptor trigger zone of the brain and on vagal afferent nerves in the gut. This inhibition prevents the activation of the vomiting reflex.

The dose of ondansetron is determined by the prescribing clinician based on the patient’s condition, age, and treatment protocol. Specific dosing regimens are not provided here.

Ondansetron should be used in pregnancy or while breastfeeding only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate each case individually.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ondansetron is a selective 5‑HT3 antagonist, offering targeted control of serotonin‑mediated nausea. Compared with dopamine antagonists or antihistamines, it generally provides more effective prevention of chemotherapy‑induced nausea with a different side‑effect profile.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat and direct light to maintain stability.

Ondansetron Sandoz is supplied as oral tablets that are taken by mouth. The exact route and timing are determined by the prescribing healthcare professional.

Serious risks include QT interval prolongation, which can lead to cardiac arrhythmias, and rare allergic reactions such as anaphylaxis. Patients should be monitored for these events, especially if they have pre‑existing cardiac conditions or are taking other QT‑prolonging drugs.

Ondansetron should be avoided in patients with known hypersensitivity to the drug or any of its components, and in individuals with a history of significant QT prolongation unless the benefits outweigh the risks.